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BY-NC-ND license (http://creativecomAbstract Background/Purposes: Monascin (MS) and ankaflavin (AK) produced by Monascus
purpureus NTU 568 were proven to show excellent hypolipidemic effects in our previous
studies; however, the mechanism is still unclear.
Methods: This study used MS, AK, and monacolin K as test substances and performed tests on
rats fed high-fat and high-cholesterol diet for 8 weeks. The lipid levels and the related protein
levels of the rats were assessed to understand the effects of MS, AK, and monacolin K on lipid
metabolism.
Results: MS and AK lowered low-density lipoprotein cholesterol (LDL-C) and preserved high-
density lipoprotein cholesterol contents. MS and AK inhibited acetyl-coenzyme A acetyltrans-
ferase, microsomal triglyceride transfer protein, and apolipoprotein (apo) B-100 expression,
thereby preventing LDL assembly. In addition, enhanced LDL-receptor expression increased
the transport of LDL-C to the liver for metabolism. MS and AK also significantly increase apo
A1 expression, which facilitates high-density lipoprotein cholesterol formation.
Conclusion: Monascus-fermented MS and AK can perform blood lipid regulation via the suppres-
sion of LDL-C assembly and stimulation of apo A1 expression in liver.
Copyright ª 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
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Low-density lipoprotein cholesterol (LDL-C) within the
vascular walls is an important risk factor for the develop-
ment of atherosclerosis.1 The occurrence of atherosclerosis
is widely attributed to poor eating habits, cardiovascular
risk factors, or genetic predisposition. Long-term con-
sumption of a high cholesterol diet can easily result in
hyperlipidemia, which induces atherosclerosis and cardio-
vascular disease.2 In 1979, the Monascus-fermented
metabolite monacolin K (MK) was found to be an effective
hypolipidemic agent.3 MK can effectively suppress the ac-
tivity of the cholesterol synthetic enzyme 3-hydroxy-3-
methylglutaryl coenzyme A reductase by preventing its
activation and thus limiting the accumulation of choles-
terol. However, because a long-term, high-dose MK may
pose safety concerns (e.g., causing rhabdomyolysis),4 the
development of new, safe hypolipidemic compounds from
Monascus-fermented products is crucial.
Studies have shown that long-term consumption of
Monascus-fermented red mold rice (RMR) prevents cardio-
vascular disease by increasing apolipoprotein (apo) A1 and
decreasing apo B100, which subsequently increases high-
density lipoprotein cholesterol (HDL-C) and LDL-C levels.5
Wei et al6 (2006) also discovered that the primary active
ingredient of Monascus-fermented RMR is not MK. However,
numerous studies have shown that Monascus-fermented red
mold dioscorea (RMD) exhibits comparatively superior
hypolipidemic and antiatherosclerosis effects than Mon-
ascus-fermented RMR. Monascus-fermented RMD signifi-
cantly reduces the total cholesterol (TC) and LDL-C levels in
the blood while increasing the level of HDL-C. In addition,
RMD exhibits a favorable total antioxidative status, cata-
lase, and superoxide dismutase activity. Research results
also show that RMD exerts favorable hypolipidemic and
antiatherosclerosis effects.7
Related studies have confirmed that the blood lipid
regulation of RMD results from monascin (MS) and anka-
flavin (AK), which, similar to MK, significantly reduces TC,
triglyceride (TG), and LDL-C levels in serum as well as
lipid plaque accumulation in the heart aorta (p < 0.05).8
Compared with MK, the effects of AK on reducing TC and
TG in serum exhibited no significant differences
(p > 0.05). However, the antifatty liver and antioxidative
stress efficacy of AK exceeds that of MK. More impor-
tantly, MS significantly enhances HDL-C concentrations,
whereas MK exerts the opposite effect.9 Concerning
safety, MK significantly increases creatine phosphokinase
activity (p < 0.05), which is highly correlated with rhab-
domyolysis. By contrast, this side effect is not observed
for MS and AK.9 Additionally, MS and AK do not pose any
potential harm to the liver, kidneys, or muscle tissue.9
Furthermore, the relatively higher MS and AK content in
RMD fermented with deep ocean water rendered the RMD
a superior agent for the prevention of cardiovascular
disease.10
Although MS and AK were proven to perform excellent
hypolipidemic effects and safety in our previous studies,8,9
the blood lipid regulation of the two substances is still
unknown. Therefore, this study is the first to investigate
the blood lipid regulation of MS and AK. This is a novel andPlease cite this article in press as: Lee C-L, et al., The blood lipid r
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To assess their effects on lipids and body fat, this study
used the yellow pigments of RMR MS and AK, as well as
cholesterol-lowering agent MK, as test substances and
performed tests on Sprague-Dawley (SD) rats that were fed
a high-fat and high-cholesterol (HFC) diet. Additionally, the
lipid and body fat levels of the rats were assessed to un-
derstand the effects of MS, AK, and MK on lipids and fat-
related metabolism. Subsequently, the protein levels of
microsomal triglyceride transfer protein (MTP), acetyl-
coenzyme A acetyltransferase (ACAT), low-density lipo-
protein receptor (LDLR), apo A1, and apo B100 proteins in
liver tissues were determined for investigating the lipid-
regulating mechanisms of MS and AK.
Materials and methods
Chemicals
Liquid chromatography grade acetonitrile, chloroform,
methanol, and dimethyl sulfoxide were purchased from
Merck Co. (Darmstadat, Germany). Tryptone, yeast extract,
peptone, malt extract, potato dextrose agar, and Bacto-
agar were purchased from Difco Co. (Detroit, MI, USA).
Monoclonal apo A1 antibody (sc-135837), MTP antibody, and
polyclonal apo B (sc-25542) antibody were purchased from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).
Monoclonal ACAT antibody (EP1375Y) and monoclonal LDLR
antibody (ab60107) were purchased from Epitomics, Inc.
(Burlingame, CA, USA).
MS and AK purification
MS and AK (99.9% purity) were purified from the RMR fer-
mented by Monascus purpureus NTU 568 according to the
method of our previous study.11
Animal experiments
Animal experiment protocol is according to our previous
study.12 Forty male SD rats at 6e8 weeks of age were pur-
chased from the BioLasco Co. (Taipei, Taiwan). The animals
were housed individually and allowed free access to a
standard laboratory chow (Ralston Purina, St Louis, MO,
USA) and water. Three weeks later, the rats were randomly
assigned to one of the following diets for 8 weeks: standard
chow (control group, NOR; 4.5% fat, 3.34 kcal/g), HFC diet
consisting of 26.7% butter powder (Gene Asia Biotech Co.,
Ltd., Nang-Tou, Taiwan) in standard chow (HFC group; 30%
fat, 0.2% cholesterol, 4.85 kcal/g), HFC þ MK (MK group),
HFC þ MS (MS group), and HFC þ AK (AK group). The rec-
ommended dosage of RMR for lowering cholesterol is sug-
gested as 2 g/d for humans in our previous study.12 RMR
included 9.82 mg/g MS, 1.425 mg/g AK, and 2.89 mg/g MK.
The dosage of MS, AK, and MK were based on the concen-
tration of RMR. The adult dose of MS (19.64 mg) in the MS
group, the adult dose of AK (2.85 mg) in the AK group, and
the adult dose of MK (5.78 mg) in the MK group were equal
to the MS, AK, and MK contents of 2-g RMR, respectively.
The doses of the test substances used in this study wereegulation of Monascus-produced monascin and ankaflavin via the
ulation of apolipoprotein A1 expression in the liver, Journal of
1016/j.jmii.2016.06.003
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area for adult humans (weight: 65 kg; height: 170 cm).13
The rats of the MS, AK, and MK groups were orally admin-
istrated 0.55 mg/d MS, 0.08 mg/d AK, and 0.16 mg/d MK for
8 weeks, respectively.
Feces were collected from rats on three consecutive
days and oven dried (65C) to a constant weight for the
determination of fat content. At the end of the study, the
rats were deprived of food for 16 hours before being scar-
ified by CO2 asphyxiation. Blood samples were collected
from the posterior vena cava and centrifuged at 700g for
10 minutes; the serum was stored at 20C until analyzed.
The livers were excised and stored at 20C for the mea-
surement of lipids. The experiment was reviewed and
approved by the Animal Care and Research Ethics Com-
mittee of the National Taitung University.
Serum, liver, and fecal lipid analysis
Serum TC, TG, and HDL-C levels were measured in tripli-
cate using commercial enzymatic kits. These kits were as
follows: the TC assay kit (CH 200, Randox Laboratories Ltd.,
Antrim, U.K.), the TG assay kit (TR-210, Randox Labora-
tories Ltd.), and the HDL-C assay kit (CH-203, Randox
Laboratories Ltd.). Serum LDL-C levels were gained via the
following calculation: LDL-C (mg/dL) ＝ TC e TG/5 e HDL-
C. Liver tissue and feces (0.5 g) were ground in 10 mL of ice-
cold Folch solution (chloroform/methanol ＝ 2:1; volume/
volume) and incubated for 30 minutes at room tempera-
ture.9 The aqueous layer was aspirated and discarded, and
the fixed concentration of the organic layer was then
evaporated to dryness. The dried lipid layer was dissolved
with an equal concentration of dimethyl sulfoxide and then
used to determine the TC and TG levels using commercial
enzymatic kits (Randox Laboratories Ltd.).
Fecal bile acid analysis
Feces powder (0.5 g) were ground in 5 mL of 100% ethanol
and extracted for 18 hours at room temperature. After
centrifugation (1800g, 15 minutes), the supernatant was
then evaporated to dryness in a vacuum. The above
extraction process was carried out three times. Petroleum
ether (10 mL) was added for extracting the organic layer.
After centrifugation (1800g, 15 minutes), the supernatant
was removed. The deposition was dissolved by methanol
(10 mL), and then used to carry out the determination of
bile acid using a commercial kit (BXC00581, Fortress Di-
agnostics Limited, Antrim, UK).
Immunoblotting
Protein concentration was determined using the bicincho-
ninic acid method. A total of 40 mg of total protein was
applied as a Western blot representative of three inde-
pendent experiments according to the previous studies.14
The samples were separated on 10% sodium dodecyl sul-
fate polyacrylamide gel electrophoresis gels and trans-
ferred to polyvinyldiene fluoride membranes. After
blocking in a gelatin-NET solution (gelatin 0.5%, NaCl 0.15
M, EDTA‧2Na 5 mM. Tween 20 0.05%, Tris base 50 mM, pHPlease cite this article in press as: Lee C-L, et al., The blood lipid r
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(1:200), monoclonal ACAT antibody (1:25000), monoclonal
LDLR antibody (1:1000), and monoclonal apo A-1 antibody
(1:1000) at room temperature for 1 hour. Then bands were
incubated with specific horse radish peroxidase-conjugated
secondary antibodies (1:100,000) at room temperature for
1 hour and visualized by enhanced chemiluminescence
substrate with UVP AutoChemi Image system (UVP Inc.,
Upland, CA, USA). Protein loading was evaluated by anti-
actin antibody (1:3,000). Band intensities were quantified
using UVP LabWork 4.5 software (UVP Inc.).15
Immunohistochemical stain
The liver tissue was fixed in 10% formalin at pH 7.4. Livers
were blocked and serial 35-mm thick frozen sections cut on
a sledge microtome were collected sequentially and
without interruption into wells. Sections from regions
containing liver were processed for polyclonal apo B-100
immunohistochemical stain. The tissue section was dried at
60C for 1 hour, then deparaffinized and hydrated,
following a dip of xylene, gradient concentration of
ethanol, and phosphate buffered saline (PBS). These sec-
tions were treated for 30 minutes in 3% hydrogen peroxide
in absolute methanol, followed by several washes with cold
PBS. After blocking in 10% normal goat serum in PBS, sec-
tions were placed in primary monoclonal apo B-100 anti-
body (1:50) diluted in antibody diluent at 4C overnight.
Labeling was detected by using the nonbiotin polyhydrogen
peroxidase immunohistochemistry detection kit (BioGenex,
San Ramon, CA, USA) and 3,3’-diaminobenzidine tetrahy-
drochloride. Counterstaining of the section was then car-
ried out with hematoxylin for 3 minutes and stopped with a
PBS wash. Sections were then mounted, air dried, and
cover slipped. The apo B-100 expression in liver were
monitored by intermittent microscope examination.16
Statistical analysis
Data are expressed as means  standard deviation. Analysis
of variance with Duncan’s test and Pearson’s product-
moment correlation coefficient test were determined
using SPSS version 10.0 software (SPSS Institute, Inc., Chi-
cago, IL, USA). Differences with p < 0.05 were considered
statistically significant.
Results
Body weight and food intake
With regards to the body weight, the animal experiment
commenced under the condition that the initial average
body weight (0th week) did not differ significantly (p > 0.05;
Table 1). However, regarding the final body weight (8th
week), the body weight of the HFC group was significantly
higher than rats fed a normal diet (NOR) group (p < 0.05).
The body weight of the MS and AK groups were significantly
lower than that of the HFC group (p < 0.05) and MK group
(p < 0.05). The final body weight was not significantly
decreased by MK administration as compared with the HFCegulation of Monascus-produced monascin and ankaflavin via the
ulation of apolipoprotein A1 expression in the liver, Journal of
1016/j.jmii.2016.06.003
Table 1 Effect of monacolin K (MK), monascin (MS), and ankaflavin (AK) on body weight and food intake in male Sprague-
Dawley rats fed with high-fat and high-cholesterol diet. Two groups of the Sprague-Dawley rats were fed a normal diet (NOR
group) or a high-fat and high-cholesterol diet (HFC group) without the administration of test materials, respectively. The other
hyperlipidemic rats were administrated with MK (0.16 mg/d 400 g body weight; MK group), MS (0.55 mg/d 400 g body weight; MS
group), and AK (0.08 mg/d 400 g body weight; AK group), respectively.
Groups Initial body weight 0th wk (g) Final body weight 8
th wk (g) Food intake,(g/d)
NOR 334  23 447  22*,*** 30.7  0.8*,**
HFC 330  21 481  24 23.1  1.5
MK 337  18 489  20 25.3  2.2
MS 336  24 424  19**,**** 21.3  3.0
AK 328  18 408  25**,**** 21.7  2.7
Data are presented as means  standard deviation (n Z 8).
* p < 0.05 versus the high-fat and high-cholesterol diet group.
** p < 0.01 versus the high-fat and high-cholesterol diet group.
*** p < 0.05 versus the monacolin K group.
**** p < 0.01 versus the monacolin K group.
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study in that MS and AK were proven to perform antiobesity
effects in obese rats fed a high fat diet.15
In Table 1, the food intake of the HFC group was signifi-
cantly lower than the NOR group (p < 0.05). This may be
because the unit calorie level of the high fat diet is higher
(HFC: 4.17 kcal/g and NOR: 3.34 kcal/g). However, the food
intake of theMS and AK groups was slightly lower than that of
the HFC group and the MK group without significant differ-
ence (p> 0.05), even though theywere fed the same high fat
diet. The reason may be that the MS and AK groups had a
lower body weight so their food intake was lower.Serum TC, TG, HDL-C, and LDL-C levels
Although our previous studies have shown that MS and AK
can perform significant hypolipidemic effects in a hamster
model,9 the blood lipid regulation of MS and AK in a rat
model has never been investigated. Therefore, in this
study, the cholesterol-lowering effect of MS and AK should
be confirmed again before the investigation of blood lipid
regulation. The changes in serum lipid levels following an 8-Table 2 Effect of monacolin K (MK), monascin (MS), and ankafla
high-density lipoprotein cholesterol (HDL-C), low-density lipoprot
Sprague-Dawley rats fed with high-fat and high-cholesterol diet.
(NOR group) or a high-fat and high-cholesterol diet (HFC group) w
other hyperlipidemic rats were administrated with MK (0.16 mg/
weight; MS group), and AK (0.08 mg/d 400 g body weight; AK gro
Groups TC
(mg/dL)
TG
(mg/dL)
LD
(m
NOR 63.1  7.8**,*** 70.3  22.8 14
HFC 98.4  16.2*** 83.9  7.1 38
MK 85.5  4.9* 74.6  6.0 31
MS 82.6  13.3* 74.4  6.8 21
AK 76.9  6.1* 64.5  14.4* 20
Data are presented as means  standard deviation (n Z 8).
* p < 0.05 versus high-fat and high-cholesterol diet group.
** p < 0.01 versus high-fat and high-cholesterol diet group.
*** p < 0.05 versus the monacolin K group.
**** p < 0.01 versus the monacolin K group.
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with NOR, although a significant increase in TG levels of the
HFC group was not observed, the levels of TC (p < 0.01) and
LDL-C (p < 0.05) and the LDL-C/HDL-C ratio (p < 0.01) in
the HFC group all exhibited a significant increase, indi-
cating that hyperlipidemia was successfully induced in the
rats. The cholesterol-lowering effects observed in each
group following the consumption of the test substances are
summarized below: MK, MS, and AK significantly reduced
the cholesterol level by 13.1% (p < 0.05), 16.0% (p < 0.05),
and 21.9% (p < 0.05), respectively. Concerning serum TG,
AK reduced TG levels by 23.1% and with a significant dif-
ference (p < 0.05).
Regarding the LDL-C reduction, compared with the HFC
group, the MK, MS, and AK groups showed a LDL-C reduction
(p < 0.05). Among the three groups, the MS and AK groups
exhibited a higher rate of LDL-C reduction compared
with that of the MK group, although this difference was not
significant (p > 0.05). HDL is negatively correlated with the
risk of cardiovascular diseases. Because the TC level of the
HFC group increased significantly (p < 0.05), the HDL-C level
of the HFC group significantly exceeded that of the NOR group
(p < 0.05). The decline in TC levels for the MK groupvin (AK) on the serum total cholesterol (TC), triglyceride (TG),
ein cholesterol (LDL-C) levels, and LDL-C/HDL-C ratio of male
Two groups of the Sprague-Dawley rat were fed a normal diet
ithout the administration of test materials, respectively. The
d 400 g body weight; MK group), MS (0.55 mg/d 400 g body
up), respectively.
L-C
g/dL)
HDL-C
(mg/dL)
LDL-C/HDL-C
ratio
.6  3.5*,*** 40.9  9.4* 0.38  0.16**,****
.3  9.2 48.6  2.7*** 0.78  0.16
.1  3.2 39.6  3.5* 0.79  0.10
.8  5.7* 47.7  5.4*** 0.47  0.16*,***
.0  8.0* 45.2  2.8 0.44  0.18*,***
egulation of Monascus-produced monascin and ankaflavin via the
ulation of apolipoprotein A1 expression in the liver, Journal of
1016/j.jmii.2016.06.003
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Conversely, a slight decrease was observed for the MS and AK
groups, and without significant difference compared with the
HFCgroup (p> 0.05). Theability ofMSandAK to reduceHDL-C
levels in serum was not affected by declines in TC levels.
Regarding the LDL-C/HDL-C ratio, compared with the HFC
group, a significant reduction was exhibited in the MS and AK
groups (p < 0.05) but not the MK group (p > 0.05). These re-
sults showed that test substances MS and AK exert superior
lipid-regulating effects than MK does.
Liver TC and TG levels
Cholesterol in the body is derived from food and the
products of the cholesterol biosynthesis pathway in the
liver. Cholesterol converts into bile acids and is eliminated
from the body via fecal excretion. Changes in the liver lipid
levels are shown in Table 3. Compared with the NOR group,
the results in Table 3 show a significant increase in TC and
TG levels in the liver of the HFC group (p < 0.05). However,
significantly decreased liver TC levels were found in the MK
(p < 0.01), MS (p < 0.05), and AK (p < 0.05) groups.
Concerning the liver TG level, compared with the HFC
group, the MK (p < 0.001) and AK (p < 0.05) groups
demonstrated the ability to significantly reduce TG levels.
The extent of this decrease for the MK group was signifi-
cantly greater than for the AK group (p < 0.05). However,
no significant difference was observed between the MS and
HFC groups. The cause of the decline in liver TC and TG may
be attributed to MK, MS, and AK inhibiting cholesterol
biosynthesis in the liver.
Fecal TC, TG, and bile acid levels
Table 3 shows the fecal TC and TG results. The amount of
fecal TC and TG may be attributable to the transportation
of lipids consumed from food to the liver via enterohepatic
circulation. Furthermore, because the HFC group was fed a
high-fat and high-cholesterol diet, their levels of TC and TG
increased, which increased TC and TG levels in theTable 3 Effect of monacolin K (MK), monascin (MS), and anka
triglyceride (TG) and fecal TC, TG, and bile acid of male Srague-D
Two groups of the Srague-Dawley rats were fed a normal diet (NOR
of test materials, respectively. The other hyperlipidemic rats we
group), MS (0.55 mg/d 400 g body weight; MS group), and AK (0.0
Groups Liver
TC (mg/g) TG (mg/g) T
NOR 20.0  3.4**,*** 74.7  9.9**,*** 5
HFC 49.1  8.3*** 145.9  18.9**** 9
MK 12.2  1.5** 55.1  4.7** 1
MS 34.9  14.9*,*** 141.1  31.8**** 7
AK 32.5  13.3*,*** 116.4  22.4*,**** 8
Data are presented as mean  standard deviation (n Z 8).
* p < 0.05 versus high-fat and high-cholesterol diet group.
** p < 0.01 versus high-fat and high-cholesterol diet group.
*** p < 0.05 versus the monacolin K group.
**** p < 0.01 versus the monacolin K group.
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in the excreted feces increased slightly for the MK and AK
groups compared with that for the HFC group (p > 0.05). In
contrast, the TC levels in the excreted feces of the MS
group significantly decreased by 26.6% (p < 0.05 vs. the HFC
group). Regarding fecal TG, the AK group exhibited a lower
excretion concentration (p < 0.05), and an insignificant
reduction (p > 0.05) was observed for the MK and MS
groups. Regarding fecal bile acid, compared with the HFC
group, the excretion concentration of the MS and AK groups
significantly increased by 41.6% (p < 0.05) and 49.2%
(p < 0.05), respectively. Meanwhile, the significant differ-
ence was not observed in the MK groups (p > 0.05).LDLR protein level in the liver
Cardiovascular diseases and LDL-C are positively corre-
lated, and negatively with the LDLR, the receptor that
recognizes LDL. Therefore, an increase of LDLR in the cell
can improve LDL-C metabolism, reducing the LDL-C levels
in blood.9
Figure 1B shows the effects that MK, MS, and AK have on
LDLR protein levels in the liver, where the LDLR protein
level of the HFC group was lower than that of the NOR
group (p < 0.05). This may be because the increase in liver
cholesterol levels for the HFC group increased LDL syn-
thesis, generating a negative feedback effect on LDLRs in
the liver. Compared with the HFC group, the MK, MS, and AK
groups all exhibited an increase in LDLR protein level.
Clinically, MK is a statin-type cholesterol-lowering drug that
not only inhibits cholesterol biosynthesis, but also increases
LDLR feedback.3,17 The 39.4% increase in LDLR protein level
observed in this experiment is consistent with that reported
in related literature.3,17 Furthermore, MS and AK increased
LDLR protein level (p < 0.01 vs. the HFC group), exceeding
that achieved by MK (p < 0.05). The substantial increase in
LDLR protein level of the MS and AK groups may be attrib-
uted to decreased cholesterol biosynthesis in the liver,
which reduces LDL synthesis, causing a feedback that sim-
ulates an increase in the synthesis of LDLRs in liver cells.flavin (AK) on the levels of liver total cholesterol (TC) and
awley rats fed with high-fat and high-cholesterol diet (HFC).
group) or a HFC diet (HFC group) without the administration
re administrated with MK (0.16 mg/d 400 g body weight; MK
8 mg/d 400 g body weight; AK group), respectively.
Feces
C (mg/g) TG (mg/g) Bile acid (mg/g)
0.8  1.9**,**** 67.8  6.2 177.8  44.1*,***
6.8  6.9 71.3  7.4 342.6  74.9
04.0  7.2 60.8  5.3 388.9  100.1
1.1  18.8*,*** 61.8  18.1 485.2  105.6*,***
7.4  7.9*** 46.1  7.5* 511.1  120.4*,***
egulation of Monascus-produced monascin and ankaflavin via the
ulation of apolipoprotein A1 expression in the liver, Journal of
1016/j.jmii.2016.06.003
Figure 1. Effect of monacolin K (MK), monascin (MS), and ankaflavin (AK) on low density lipoprotein receptor (LDLR), acetyl-
coenzyme A acetyltransferase (ACAT), microsomal triglyceride transfer protein (MTP), and apolipoprotein (apo) A1 protein level
in liver of male Sprague-Dawley rats fed with high-fat and high-cholesterol diet (HFC). Two groups of the Sprague-Dawley rats were
fed a normal diet (NOR group) or a HFC diet (HFC group) without the administration of test materials, respectively. The other
hyperlipidemic rats were administrated with MK (0.16 mg/d 400 g body weight; MK group), MS (0.55 mg/d 400 g body weight; MS
group), or AK (0.08 mg/d 400 g body weight; AK group), respectively. * p < 0.05 versus the high-fat and high-cholesterol diet group.
** p < 0.01 versus the high-fat and high-cholesterol diet group. *** p < 0.05 versus the monacolin K group. **** p < 0.01 versus the
monacolin K group.
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The primary function of ACAT is to catalyze long-chain fatty
acids and cholesterol into cholesteryl ester, which is then
transferred using MTP to newly synthesized apo B to form
very-LDL (VLDL).18 Therefore, ACAT is a key enzyme in LDL-
C synthesis and positively correlates with cardiovascular
disease.19 Figure 1C shows the effect that MK, MS, and AK
consumption has on ACAT protein level in liver tissues.
Compared with the NOR group, the ACAT protein level of
the HFC group increased slightly (p > 0.05). Considering the
effects of consummation of the test substances on the
reduction of ACAT protein levels, the reduction yielded by
AK was the highest (p < 0.001), followed by that yielded by
MS (p < 0.01) and MK (p < 0.05).
MTP expression in the liver
MTP can transport TG, cholesteryl ester, and phospholipids
in cells to newly synthesized apo B.20 This process is critical
for the formation and secretion of lipoproteins containing
apo B, such as VLDL, LDL, and chylomicrons (CM).21 Because
apo B is the apolipoprotein of LDL-C, MTP is positively
correlated with cardiovascular disease.
Figure 1D shows the effects that MK, MS, and AK con-
sumption has on MTP expression in liver tissues. No signifi-
cant difference in MTP level was observed between the HFC
and NOR groups (p > 0.05). This indicates that HFC diets do
not exert a considerable effect on the transfer of lipids by
MTP. MK was default to decrease the high fat diet-raised
MTP level (p > 0.05 vs. the HFC group). However,
compared with the HFC and MK groups, the MS (p < 0.05)
and AK (p < 0.01) groups showed a significant reduction in
MTP expression. This may be because the earlier meta-
bolism phase limited cholesterol synthesis, lowering the
overall level of cholesterol in the body, which decreased
the conversion of cholesterol into cholesteryl ester by
ACAT, thereby reducing the expression of MTP for trans-
ferring cholesteryl ester.
Apo A1 protein level in the liver
HDL transports cholesterol from surrounding tissues to the
liver for metabolization, thereby cleaning the vascular
walls. The higher the serum HDL-C level, the better the
body’s ability to transport serum cholesterol to the liver for
metabolism, which reduces the likelihood of developing
atherosclerosis.22 Apo A1 is an apolipoprotein of HDL.
Increased level of apo A1 increases HDL synthesis, which
subsequently reduces the risk of developing cardiovascular
disease. Thus, apo A1 and cardiovascular disease are
negatively correlated.
Figure 1E shows the effects that MK, MS, and AK con-
sumption have on apo A1 protein levels in liver tissue. No
significant differences in apo A1 protein level were
observed between the HFC group and the NOR group
(p > 0.05). Compared with the HFC group, the increase in
apo A1 protein level of the MS group was the most signifi-
cant (p < 0.001), followed by those of the AK (p < 0.01) and
MK (p < 0.05). By increasing the expression of apo A1
protein, HDL synthesis also increased. To understand thePlease cite this article in press as: Lee C-L, et al., The blood lipid r
suppression of low-density lipoprotein cholesterol assembly and stim
Microbiology, Immunology and Infection (2016), http://dx.doi.org/10.mechanism of how increases in MS and AK increase the
expression of apo A1 protein, further studies must be
performed.
Apo B protein level in the liver
Numerous studies have confirmed that LDL is responsible
for atherosclerosis development, and apo B-100 is indis-
pensable in the formation of VLDL and LDL.23,24 Therefore,
reducing apo B-100 decreases the formation of VLDL and
LDL, thereby minimizing the development of cardiovascular
disease.25 Thus, apo B and cardiovascular disease can be
considered positively correlated.
Figure2 shows theeffects thatMK,MS,andAKconsumption
haveonapoB-100protein level in the liver.Comparedwith the
NOR group, apo B-100 protein level in the HFC group rose
significantly (p< 0.001), which indicates that LDL synthesis in
the HFC group had increased. However, compared with the
HFC group, MK, MS, and AK groups all achieved significant
reductions in apo B-100 protein level (p < 0.001). Literature
shows that lovastatin can lower apo B-100 protein levels,26
which is consistent with the results obtained for the MK
group in this study.Furthermore, theexperimentconducted in
this study was the first time that MS and AK were observed to
effectively reduce the expression of apo B-100 protein in the
liver. The effects of both MS and AK significantly exceeded
those of MK (p < 0.05).
Discussion
MS and AK are nature Monascus-fermented yellow pigments
without liver damage that are abundantly produced in
RMD.8 Relevant studies have shown that MS and AK can
significantly reduce LDL-C and increase HDL-C.9 Further-
more, unlike MK, MS and AK do not increase creatine
phosphokinase activity, which elevates the risk of rhabdo-
myolysis.9 Therefore, MS and AK are safe and effective
lipid-lowering agents. In Table 2, the blood biochemical
assay results show that both MS and AK can significantly
lower TC and TG concentrations, which is consistent with
that reported by previous studies.8,9 The MS and AK groups
showed significant reductions in LDL-C levels (p < 0.05),
respectively. However, the blood lipid regulation mecha-
nism of MS and AK remain unknown. Therefore, this study
examined the influence of MS and AK on lipoprotein for-
mation and metabolism, to understand the path through
which MS and AK regulate blood lipids.
Concerning the absorption and regulation of cholesterol
in the body, 30% of cholesterol from food is absorbed by the
small intestine. Bile acid is also absorbed by the small in-
testine before being transferred to the liver through
enterohepatic circulation and stored in the gallbladder as
reserve. Only a small portion of bile acid is excreted in
feces. The bile acid that assists food fat absorption is also
derived from cholesterol.27 The largest proportion of
endogenous cholesterol in the human body is secreted by
the liver, accounting for 50% of the total concentration,
followed by the small intestine, which accounts for
approximately 15% of all cholesterol. The cholesterol
absorbed by the small intestine is converted into choles-
teryl ester and then CM before entering the enterohepaticegulation of Monascus-produced monascin and ankaflavin via the
ulation of apolipoprotein A1 expression in the liver, Journal of
1016/j.jmii.2016.06.003
Figure 2. Effect of monacolin K (MK), monascin (MS), and ankaflavin (AK) on apolipoprotein (apo) B100 protein level in the liver
of male Sprague-Dawley rats fed with a high-fat and high-cholesterol (HFC) diet. Two groups of the Sprague-Dawley rats were fed a
normal diet (NOR group) or a HFC diet (HFC group) without the administration of test materials, respectively. The other hyper-
lipidemic rats were administrated with MK (0.16 mg/d 400 g body weight; MK group), MS (0.55 mg/d 400 g body weight; MS group),
and AK (0.08 mg/d 400 g body weight; AK group), respectively. * p < 0.001 versus high-fat and high-cholesterol diet group. **
p < 0.05 versus the monacolin K group. *** p < 0.001 versus the monacolin K group.
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+ MODELcirculation. Although the cholesterol-lowering mechanism
remains unclear, the results of this study show that MS and
AK can significantly enhance bile acid concentrations,
which facilitate the excretion of cholesterol in feces. The
increase in bile acid may be attributable to a high HDL-C
content, collecting and transporting cholesterol from sur-
rounding tissues to the liver where it is metabolized to form
bile acid.28 In addition, the increase in LDLR also prompts
the transportation of LDL-C to the liver for metabolism.29
However, MK only slightly increased the amount of bile
acid (Table 3), which may be attributable to the significant
decline in level of HDL-C, causing fewer amount of
cholesterol to be transported to the liver for metabolism.
Previous studies have shown that MS and AK can signifi-
cantly reduce the expression of Niemann-Pick C1-like 1
(NPC1L1) protein.15 NPC1L1 is a crucial enzyme that isPlease cite this article in press as: Lee C-L, et al., The blood lipid r
suppression of low-density lipoprotein cholesterol assembly and stim
Microbiology, Immunology and Infection (2016), http://dx.doi.org/10.absorbed by cholesterol in the small intestine. By inhibiting
NPC1L1 expression, MS and AK can reduce the absorption of
cholesterol. Therefore, the bile acid, which is excreted to
the small intestine due to MS and AK induction, is less
frequently absorbed by the small intestine because of the
inhibited NPC1L1 expression, thereby reducing cholesterol
concentrations.
The results of this study and previous studies confirm
that MS and AK can reduce TC and TG concentrations in the
serum and liver, which significantly decreases LDL-C con-
tent while retaining HDL-C. MS and AK were proven to in-
crease HDL-C content in several studies but maintained in
this study.8e10 However, the animal model of this study is a
high-fat diet-induced hyperlipidemic rat which is different
to the hamster animal model in our previous studies. Cho-
lesteryl ester transfer protein, which promotes the transferegulation of Monascus-produced monascin and ankaflavin via the
ulation of apolipoprotein A1 expression in the liver, Journal of
1016/j.jmii.2016.06.003
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proteins, including VLDLs, VLDL remnants, intermediate
density lipoproteins, and LDLs, is expressed in the hamster
model but not in the rat model. This discrepancy may lead
to a different HDL regulation in hamster and rat models.
This study further explored the effects that MS and AK have
on the expression of proteins that regulate LDL-C and HDL-C
concentrations to understand how MS and AK reduce LDL-C
concentrations while maintaining the HDL-C concentration.
Cholesterol synthesized in the body may induce ACAT
expression, which transforms cholesterol into cholesteryl
ester. Subsequently, the cholesteryl ester is transported by
MTP and combined with apo B-100 to form LDL. The LDL
then carries cholesterol, forming LDL-C and leading to the
accumulation of cholesterol on vascular walls, which results
in atherosclerosis development.23,24 LDL-C and cardiovas-
cular disease are positively correlated. If the LDLR protein
level increases, LDL metabolism is improved, reducing the
level of LDL-C in the blood.17 HDL, including the apo A1,
collects and transports cholesterol from surrounding tissues
to the liver for metabolism. Thus, HDL possesses vascular
wall-cleaning efficacy, and the HDL-C level and apo A1
content are both the important factors for reducing the risk
of cardiovascular disease.30,31
Based on the results in Table 3, the decline in liver TC
levels can be inferred to result from the inhibition of
endogenous cholesterol biosynthesis. MS can inhibit the
merging of cholesterol and LDL in the liver, forming LDL-C.
Figure 1 shows that both MS and AK can significantly sup-
press ACAT protein level. At this stage, MS and AK signifi-
cantly suppress the conversion of free cholesterol into
cholesteryl ester. MS and AK also reduce MTP expression,
thereby limiting the transport of cholesteryl ester by MTP.
Thus, cholesteryl ester cannot bond with apo B to form CMF
chole
VLDL-C
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Apo B
LDLR
H
MTP
Tri
VLDL-C
IDL-C
LRP
SR-B1
ox-LDL-C
Liver
Figure 3. The regulation of low density lipoprotein (LDL) and high
in the liver. apo B Z apolipoprotein B; ACAT Z acetyl-coenzyme A
cholesterol; LDLRZ low-density lipoprotein receptor; LRPZ low d
triglyceride transfer protein; ox-LDL-CZ oxidized-low-density lipop
C Z very low density lipoprotein-cholesterol.
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that the regulating effects of MS and AK also significantly
reduce apo B-100 content. Consequently, the CM required
for LDL-C and downstream VLDL-C formation cannot be
produced because ACAT, MTP, and apo B-100 expressions
are inhibited by MS and AK. The serial effects of MS and AK
prevent the conversion of free cholesterol into LDL-C.
Additionally, regarding serum LDL-C removal, MK and AK
increase the expression of LDLR protein in the liver by 67.1%
and 74.5%, respectively. This effect enhances LDL meta-
bolism, subsequently reducing LDL-C levels in the blood.
Based on these results, MS and AK reduce LDL-C concen-
trations in the serum by inhibiting LDL-C formation and
enhancing LDL-C metabolism.
HDL transports cholesterol from surrounding tissues to
the liver for metabolism, thereby exhibiting vascular wall-
cleaning efficacy.31 Therefore, low HDL-C levels may in-
crease the development of cardiovascular disease. A
decrease in apo B-100 expression and increase in apo A1
expression guides free cholesterol to the biosynthesis
pathway to form HDL-C. Figure 1E shows that MS and AK can
significantly increase apo A1 protein level in the liver. The
results of previous studies show that reducing the expres-
sion of ACAT, MTP, and apo B-100 inhibits the formation of
LDL-C.23,24 Therefore, free cholesterol may shift to undergo
the biosynthesis pathway of HDL-C, which explains the
result that HDL-C concentration in the presence of MS and
AK did not decline because of a decrease in TC.
The results of this study show that MK, MS, and AK
exhibit varying lipid-regulation effects. In addition,
although all three substances can significantly reduce TC
and TG, MK differs from MS and AK in that it possesses
weaker LDL-C reduction effects and stronger HDL-C
reduction results. However, regarding protein levels, MKree 
sterol
Cholesterol ester
Apo A1
DL-C
ACAT
Bile acid
glyceride
Free 
cholesterol
density lipoprotein (HDL) assembly by monascin and ankaflavin
acetyltransferase; IDL-C Z intermediate density lipoprotein-
ensity lipoprotein receptor-related protein; MTPZ microsomal
rotein-cholesterol; SR-B1Z scavenger receptor class B1; VLDL-
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indicating that MK is inferior to MS and AK for inhibiting LDL-
C formation and inducing LDL-C transport to the liver for
metabolism. This indicates that MS and MK exert superior
LDL-C reduction effects. Concerning HDL-C regulation, MK
can significantly reduce HDL-C concentrations, possibly
because MK cannot significantly increase apoA1 expression
(Figure 1E). Consequently, declines in the TC concentration
significantly reduce HDL-C concentrations. Based on the
preceding discourse, this study infers that the lipid-
regulating methods of MS and AK differ from that of MK.
MK reduces the conversion of free cholesterol into LDL-C
and HDL-C by limiting cholesterol synthesis. Therefore,
despite lowering LDL-C concentrations, MK cannot prevent
a decline in HDL-C, which consequently causes athero-
sclerosis. Conversely, by inhibiting LDL formation, accel-
erating the metabolic process of recycled LDL-C, and
increasing apo A1 expression, MS and AK not only reduce TC
and LDL-C content, but also preserve HDL-C concentra-
tions. This study attempted to understand their regulation
on LDL-C synthesis. In future studies, details on blood lipid
regulation should continue to be carried out with in-vitro
and in-vivo studies. MS and AK may be novel natural
hypolipidemic compounds for functional food and medicine
developments in the future.
Conclusion
This study confirms that MS and AK possess significant
cholesterol-lowering effects and the ability to preserve HDL-
C content. HDL-C induces the transport of cholesterol to the
liverwhere cholesterol ismetabolized into bile acid, which is
subsequently excreted, lowering the overall cholesterol
level. The lipoprotein regulations ofMS andAK are concluded
in Figure 3. MS and AK can inhibit ACAT, MTP, and apo B-100
expression, thereby preventing LDL formation. In addition,
enhanced LDLR expression increases the transport of LDL-C
to the liver for metabolism. Regarding HDL-C regulation, MS
and AK significantly increase apo A1 expression, which fa-
cilitates HDL-C formation. The effects exerted by MS and AK
on various lipoprotein regulatory factors significantly
exceeded that of MK, particularly, in increasing apo A1
expression. This is also the reason that, unlike MK, MS and AK
do not induce a significant decline in HDL-C. This study is the
first to investigate the blood lipid regulation of MS and AK.
This finding of blood lipid regulation will be of benefit to the
development of the two novel hypolipidemic compounds
produced by natural M. purpureus on functional food and
medicine developments in the future.
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